ArticleOncology reports2019

Evaluation of the STAT3 inhibitor GLG‑302 for the prevention of estrogen receptor‑positive and ‑negative mammary cancers.

Robert H Shoemaker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.